A clinical perspective of chitosan nanoparticles for infectious disease management

Dilnawaz, Fahima; Acharya, Sarbari; Kanungo, Anwesha

doi:10.1007/s00289-023-04755-z

Cited by 3 publications

(3 citation statements)

References 108 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 However, the currently prevailing understanding of CS action involves primary interactions with bacterial envelopes and their disruption, potentially leading to interactions with internal components. 59–61…”

Section: Resultsmentioning

confidence: 99%

Exploring the antimicrobial potential of chitosan nanoparticles: synthesis, characterization and impact on Pseudomonas aeruginosa virulence factors

Maršík,

Maťátková,

Kolková

et al. 2024

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Exploring the antimicrobial potential of chitosan nanoparticles: synthesis, characterization and impact on Pseudomonas aeruginosa virulence factors

Maršík,

Maťátková,

Kolková

et al. 2024

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…Infectious diseases have consistently remained a significant global threat to public health over the past few decades . Among the various infectious diseases, brucellosis stands out as a widespread infectious zoonosis that is observed worldwide.…”

Section: Introductionmentioning

confidence: 99%

“…Infectious diseases have consistently remained a significant global threat to public health over the past few decades. 1 Among the various infectious diseases, brucellosis stands out as a widespread infectious zoonosis that is observed worldwide. Recognized by the World Health Organization as one of the most severe bacterial diseases transmitted between animals and humans, brucellosis continues to pose a serious threat to public health around the world, particularly in developing nations.…”

Section: Introductionmentioning

confidence: 99%

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

Hernández-Giottonini,

Arellano-Reynoso,

Rodríguez-Córdova

et al. 2023

ACS Omega

View full text Add to dashboard Cite

The in vivo efficacy of rifampicin encapsulated in poly(lactic- co -glycolic acid) (PLGA) nanoparticles was evaluated for the treatment of BALB/c mice experimentally infected with Brucella canis . The PLGA nanoparticles loaded with rifampicin (RNP) were prepared using the single emulsification-solvent evaporation technique, resulting in nanoparticles with a hydrodynamic diameter of 138 ± 6 nm. The zeta potential and polydispersity index values indicated that the system was relatively stable with a narrow size distribution. The release of rifampicin from the nanoparticles was studied in phosphate buffer at pH 7.4 and 37 °C. The release profile showed an initial burst phase, followed by a slower release stage attributed to nanoparticle degradation and relaxation, which continued for approximately 30 days until complete drug release. A combined model of rifampicin release, accounting for both the initial burst and the degradation–relaxation of the nanoparticles, effectively described the experimental data. The efficacy of RNP was studied in vivo ; infected mice were treated with free rifampicin at concentrations of 2 mg per kilogram of mice per day (C1) and 4 mg per kilogram of mice per day (C2), as well as equivalent doses of RNP. Administration of four doses of the nanoparticles significantly reduced the B. canis load in the spleen of infected BALB/c mice. RNP demonstrated superior effectiveness compared to the free drug in the spleen, achieving reductions of 85.4 and 49.4%, respectively, when using C1 and 93.3 and 61.8%, respectively, when using C2. These results highlight the improved efficacy of the antibiotic when delivered through nanoparticles in experimentally infected mice. Therefore, the RNP holds promise as a potential alternative for the treatment of B. canis .

show abstract

Applications of Nanochitosan in Fish Disease Management

Iheagwam,

Amuji,

Mamudu

2024

Nanochitosan-Based Enhancement of Fisheries and Aquaculture

View full text Add to dashboard Cite

A clinical perspective of chitosan nanoparticles for infectious disease management

Cited by 3 publications

References 108 publications

Exploring the antimicrobial potential of chitosan nanoparticles: synthesis, characterization and impact on Pseudomonas aeruginosa virulence factors

Exploring the antimicrobial potential of chitosan nanoparticles: synthesis, characterization and impact on Pseudomonas aeruginosa virulence factors

Enhancing Therapeutic Efficacy against Brucella canis Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles

Applications of Nanochitosan in Fish Disease Management

Contact Info

Product

Resources

About